Cardiac contractility and conduction: a comparison of antihypertensives

B Greenberg1

  • 1Division of Cardiology, Oregon Health Sciences University, Portland 97201-3098.

Insights

This review examines first-line antihypertensive agents, focusing on their cardiac effects in patients with cardiovascular disease. Diuretics and ACE inhibitors have minimal cardiac impact, while beta-blockers and calcium channel blockers offer specific benefits and considerations.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The 1988 Joint National Committee report recommended four classes of first-line antihypertensive agents.
  • Understanding the cardiac effects of these agents is crucial for patients with co-existing cardiovascular diseases.

Purpose of the Study:

  • To review the cardiac effects of first-line antihypertensive agents.
  • To assess the impact of these agents on heart rate, atrioventricular nodal conduction, and myocardial contractility.

Main Methods:

  • Review of existing literature on antihypertensive agents.
  • Analysis of effects on cardiac parameters in patients with cardiovascular conditions.

Main Results:

  • Diuretics and angiotensin-converting enzyme inhibitors exhibit no significant direct cardiac effects.
  • Beta-blockers can inhibit cardiac stimulation and benefit patients post-myocardial infarction.
  • Calcium channel blockers, though heterogeneous, can be selected for potent peripheral vasodilation to minimize cardiac effects.

Conclusions:

  • The choice of antihypertensive agent should consider its specific cardiac effects, especially in patients with cardiovascular disease.
  • Newer agents like isradipine show promise for targeted arterial vasodilation and improved safety profiles.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...